Randomised, Double-Blind, Multi-Centre, 12 Month Extension Study to Evaluate the Safety And Efficacy of Daily Budesonide MMX 6 mg Versus Placebo in the Maintenance of Remission in Subjects With Ulcerative Colitis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide (Primary)
Indications Ulcerative colitis
Focus Registrational; Therapeutic Use
Sponsors Bausch Health Companies; Salix Pharmaceuticals

Most Recent Events

22 May 2012 Tolerability analysis assessing the effects of treatment on bone mineral density presented at Digestive Disease Week 2012.
22 May 2012 Results presented at the Digestive Disease Week 2012.
18 May 2012 Further analyses will be reported at the 2012 Digestive Disease Week meeting, according to a Santarus media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight